Zacks.com Announces That Vivian Lewis Highlights the Following Stocks: Sanofi, Spirent Communications, Taro and Teva.

Business Editors

CHICAGO--(BUSINESS WIRE)--Feb. 5, 2004

Vivian Lewis says that China could be the next financial mania, so investors had better be careful. Make sure that your investment tour is a profitable one with this expert's market and stock information. Read about Sanofi (NYSE:SNY), Spirent Communications (NYSE:SPM), Taro (NASDAQ:TARO), and Teva (NASDAQ:TEVA). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

Here are the highlights from the Featured Expert column:

According to Bank Credit Analyst, an excellent Canadian forecasting outfit, China could be the next financial mania. The BCA service cites the "electrifying" rise in Chinese stocks and notes that history has demonstrated that mania forces develop in waves. "They tend to drive asset prices to a series of climactic highs before a dramatic and painful shakeout." It warns: "The pattern of the recent China mania is eerily similar to the spectacular run up in Chinese stocks in 1992-94 and 1996-97."

Vivian Lewis' own preference is for Argentina and India.

Taking Stock...

Sanofi (NYSE:SNY) made an unfriendly offer to take control of Aventis (NYSE:AVE), the Franco-German drug group, and its shares are suffering as a result. Apart from normal arbs, SNY is on the bear hit list because of the termination of its key shareholder agreements with Total and L'Oreal by the end of the year, and fears that its blockbuster Plavix will run into patent challenges.

Spirent Communications (NYSE:SPM) made a strong push for the lead in its core mobility test equipment market with a new product and a new partner. SPM introduced the first carrier-scale CDMA2000 performance benchmarking tool, co-developed with Scientific Software Engineering, provider of software telecommunications products for more than 20 years. The new CDMA2000 Performance Test System builds upon existing test tools for GPRS, WCDMA and WLAN. The new partnership will yield several future wireless core infrastructure test applications.

Taro's (NASDAQ:TARO) U.S. affiliate had expanded its distribution capacity by buying a distribution center in South Brunswick (NJ) for $18 million, for which it will receive financial incentives from the State. It also has research, production, and distribution activities in Israel, Canada, and Ireland.

Teva (NASDAQ:TEVA) was rated "outperform" by William Blair and Lewis' Tel Aviv gossips say that it will exceed its own estimates this quarter. It won FDA okay for 2 new generic oral contraceptives from its deal with Andrx. These have sales of $713 million and $137 million/year respectively.

Read all of Vivian Lewis and her team's commentaries, along with much more stock information, by clicking: http://at.zacks.com/?id=85

About Zacks Featured Experts

To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Recommendations from Featured Experts Highlighted in FREE Investment Newsletter

The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://at.zacks.com/?id=87

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.